The company is owned totally by the founders.

PUBLIC FUNDS

Medchemfarma has received NEOTEC 2025 funding for the implementation of its project entitled “Discovery and development of new PPAR-Ƴ receptor covalent agonists for the local treatment of respiratory diseases” (RESPPAR) Exp: SNEO-20251059. The overall objective of this project is the discovery and preclinical development of nuclear receptor agonists for inhaled administration. The compounds are designed to achieve high retention in the lungs, enabling its use as a treatment for COPD to reduce exacerbations and consequently slow down the progressive deterioration of patients.

Grant awarded: €325,000.00

This grant has been subsidised by the CDTI and supported by the Ministry of Science, Innovation and Universities.

Medchemfarma has been awarded funding under the Public-Private Projects 2024 call for the implementation of the project entitled “Discovery and early-stage development of first organ-restricted DHODH inhibitors to reduce toxicity profile (DHODH-INHIB)” (Exp: CPP2024‑011376), as part of the consortium established together with the University of Santiago de Compostela and the University of Barcelona.

This project is funded by MICIU/AEI/10.13039/501100011033 and by FEDER, EU.

Medchemfarma has been beneficiary in the call for start-up capital grants for emerging technology companies for the year 2023, through Acciò Program (https://accio.gencat.cat) to carry out the Project: New cancer treatments based on covalent kinase inhibitors as immuno-oncological therapies (ACE087/23/000052)

Medchemfarma is participating in the project: “HPK1‑INHIB – Discovery and preclinical development of new compounds as hpk1 inhibitors for cancer treatment” (CPP2022‑009716), as the leading entity of the Consortium formed together with: ACONDICIONAMIENTO TARRASENSE – LEITAT, and UNIVERSIDAD DE SANTIAGO DE COMPOSTELA (USC – BIOFARMA Group).

The main objective of the project is the discovery and preclinical development of new HPK1 inhibitors, as well as conducting in vitro and in vivo efficacy studies with these new compounds. The project is scheduled to be carried out between March 2023 and March 2026.

The project has been funded by MCIN/AEI/10.13039/501100011033 and by the European Union – NextGenerationEU/PRTR.